Yeah that wouldn’t be ideal haha! That’s why I’d say they are fairly confident in what the outcome will be. The primary endpoint will be around lesion detection and we already have data suggesting that SAR-bisPSMA is superior (eg COBRA). This trial is simply to confirm this data we already have
CU6 Price at posting:
$6.74 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)